Less Ads, More Data, More Tools Register for FREE

Pin to quick picksItaconix Plc Regulatory News (ITX)

Share Price Information for Itaconix Plc (ITX)

Share Price is delayed by 15 minutes
Get Live Data
113.50    0.00 (0.00%)
Bid:
110.00
Ask:
117.00
Spread: 7.00 (6.364%)
Market Cap: £15.31m
ITX Live PriceLast checked at - London Stock Exchange

Intraday Itaconix Plc Share Chart

Full Year Trading Update

13 Jan 2026 07:00

RNS Number : 5928O
Itaconix PLC
13 January 2026
 

For release: 07.00, 13 January 2026

Itaconix plc

("Itaconix" or the "Company")

Full Year Trading Update

Record revenues exceeding $10 million for the first time, driven by third consecutive record half year and strong customer momentum

Itaconix plc (AIM: ITX) (OTCQB: ITXXF), a leading innovator in high-performance plant-based specialty polymers, is pleased to provide a trading update for the year ended 31 December 2025.

Unaudited revenues for FY 2025 increased 59% year-on-year to $10.3 million (FY 2024: $6.5 million), exceeding $10 million for the first time. This performance was underpinned by a third consecutive record half year, with revenues of $5.5 million in H2 2025, up from $4.8 million in H2 2024.

Revenue growth was generated across both existing and new customers, spanning major applications and geographies. Demand for the Company's patented plant-based polymers continued to strengthen as global consumer product manufacturers increasingly adopt sustainable, high-performance ingredients to enhance formulation performance and deliver added value in detergent, hygiene and beauty products. This growth in revenue and a step change in the Company's commercial traction have enabled Itaconix to invest further in demand generation and support for 2026.

The Board remains optimistic about the Company's prospects for 2026 and believes that Itaconix is well positioned to deliver continued revenue growth, supported by a growing customer pipeline, expanding product adoption and a scalable, capital-efficient operating model. 

Further details on 2025 trading performance and the outlook for 2026 will be provided with the Company's FY 2025 results, expected in late March 2026.

John R. Shaw, CEO of Itaconix, commented:

"2025 was a milestone year for Itaconix. Delivering record revenues of over $10 million for the first time, alongside our third consecutive record half year, demonstrates the accelerating commercial momentum behind our technology and customer proposition.

"We are seeing growing validation from both new and existing customers as our plant-based specialty polymers become embedded in next-generation consumer products where performance, sustainability and value are all critical.

"Entering 2026, Itaconix is operating from a position of strength: we are well funded, capital efficient and supported by a deep and expanding revenue pipeline. With increasing scale, disciplined execution and strong customer engagement, we believe the Company is firmly on track towards building a large, profitable and enduring specialty ingredients business, delivering long-term value for shareholders."

- ends -

Enquiries:

Itaconix plc +1 603 775 4400

John R. Shaw / Laura Denner

Rosewood +44 (0) 207 653 8704

Financial PR

John West / Llewellyn Angus / Lily Pearce

Canaccord Genuity +44 (0) 7523 8000

Nominated Adviser and Broker

Adam James / Harry Pardoe

 

About Itaconix

Itaconix uses its proprietary plant-based polymer technology platform to produce and sell specialty ingredients that improve the safety, performance, and sustainability of consumer products. The Company's current ingredients are enabling and leading new generations of cost-effective, decarbonized consumer products in home and personal care.

www.itaconix.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBIGDBXBBDGLD
Date   Source Headline
11th May 20157:05 amRNSDirector Declaration
5th May 20157:01 amRNSDirector/PDMR Shareholding
13th Apr 20157:00 amRNSNotice of AGM
30th Mar 20157:00 amRNSPreliminary Results
24th Mar 20157:15 amRNSDirector Declaration
9th Jan 20157:00 amRNSBlocklisting Interim Review
5th Jan 201512:00 pmRNSTotal Voting Rights
11th Dec 20147:00 amRNSHolding(s) in Company
10th Nov 20147:00 amRNSPatent Infringement Settled and Discontinued
10th Oct 20144:22 pmRNSTotal Voting Rights
29th Sep 20147:00 amRNSInterim Results
25th Sep 20147:00 amRNSGlobal licence signed with Solvay
26th Aug 20147:00 amRNSNew CEO start date confirmed
9th Jul 20147:00 amRNSBlocklisting Interim Review
4th Jul 20147:00 amRNSAppointment of Chief Executive Officer
2nd Jul 20147:00 amRNSTotal Voting Rights
23rd Jun 20147:01 amRNSNotification of Major Interest in Shares
23rd Jun 20147:00 amRNSNotification of Major Interest in Shares
9th Jun 20147:00 amRNSUS supply agreement for nicotine chewing gum
3rd Jun 20147:00 amRNSTotal Voting Rights
22nd May 201412:34 pmRNSResult of AGM
30th Apr 20143:16 pmRNSNotification of Major Interest in Shares
24th Apr 20147:00 amRNSAward under Long Term Incentive Plan
23rd Apr 201412:45 pmRNSNotification of Major Interest in Shares
23rd Apr 20147:00 amRNSNotice of AGM
22nd Apr 201411:58 amRNSTotal Voting Rights
14th Apr 20147:00 amRNSAward of Technology Strategy Board funding
31st Mar 20147:00 amRNSPreliminary Results
3rd Mar 20147:00 amRNSTotal Voting Rights
30th Jan 201411:39 amRNSBlock Listing
27th Jan 20147:00 amRNSDirectorate Change
24th Jan 20144:46 pmRNSHolding(s) in Company
10th Jan 20147:00 amRNSBlock Listing Six Monthly Return
20th Nov 20137:00 amRNSMarketing approval of nicotine gum in Europe
17th Oct 20137:00 amRNSSupply and Distribution Agreement with Amma Polska
11th Oct 20137:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
25th Sep 20137:00 amRNSInterim Results
1st Aug 20137:00 amRNSTotal Voting Rights
22nd Jul 20137:00 amRNSAward of contract to supply nicotine gum
15th Jul 201312:20 pmRNSChange of Registered Office
9th Jul 20137:00 amRNSBlocklisting Interim Review
28th May 20132:02 pmRNSResult of AGM
17th Apr 20134:47 pmRNSHolding(s) in Company
17th Apr 20137:00 amRNSDirector's Dealings
9th Apr 20137:00 amRNSPositive test results for encapsulation technology
22nd Mar 20137:00 amRNSNotice of AGM and Posting of Annual Report
13th Mar 20137:00 amRNSPreliminary Results
1st Mar 20137:00 amRNSTotal Voting Rights
1st Feb 20132:42 pmRNSNotice of patent infringement proceedings
10th Jan 20137:01 amRNSAwards under Long Term Incentive Plan

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.